• AG-221 (Enasidenib): From 2-HG to Assay Design

  2026-09-07

  AG-221 (Enasidenib) is more than an IDH2 inhibitor: it is a tool for connecting 2-hydroxyglutarate reduction with epigenetic recovery, metabolic state, and leukemia cell differentiation. This article explains how recent CD44 findings can sharpen assay design in acute myeloid leukemia research.

• From Vaccine Breadth to Better Antibody Readouts

  2026-09-07

  Broad-spectrum vaccine development depends on more than demonstrating neutralization in animal models. This thought-leadership article explains how mechanistic assay design, species-aware detection, and the HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody can help translational teams convert human IgG measurements into reproducible evidence without confusing binding signals with functional protection.

• GKT137831: Dual Nox1/Nox4 Redox Workflows

  2026-09-05

  GKT137831 is a practical dual NADPH oxidase Nox1/Nox4 inhibitor for connecting ROS biology with vascular, fibrotic, metabolic, and membrane-damage assays. This guide provides concentration planning, ferroptosis-oriented readouts, workflow controls, and troubleshooting strategies for reproducible research use.

• AG-221 (Enasidenib): Assay Logic for IDH2 AML

  2026-09-04

  AG-221 (Enasidenib) enables a mechanism-led approach to IDH2-mutant AML research. This article shows how to connect 2-hydroxyglutarate reduction with differentiation, metabolic-state measurements, and CD44-dependent vulnerability rather than relying on viability alone.

• Chlorambucil: Separating Growth Arrest from Cell Death

  2026-09-04

  Chlorambucil is a nitrogen mustard alkylating agent whose DNA damage can produce both cytostasis and cell death. This guide applies a dissertation-derived framework to improve assay interpretation, distinguish relative from fractional viability, and design more informative cancer-cell experiments.

• How Inhibitors Accelerate p38α Dephosphorylation

  2026-09-03

  The reference preprint shows that some kinase inhibitors can do more than block p38α catalysis: they can also reshape its activation loop to make the regulatory phosphothreonine a better substrate for WIP1 phosphatase. This dual-action concept offers a biochemical framework for designing more durable and potentially more selective kinase inhibition, while requiring validation beyond the recombinant system.

• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-09-03

  Zhou et al. identify TSPAN18 as a previously unrecognized regulator of STIM1 stability and show that it promotes prostate cancer bone metastasis through TRIM32-dependent control of calcium entry. The study connects a protein-interaction mechanism with metastatic phenotypes, providing a framework for investigating the STIM1–Ca2+ axis in prostate cancer research while highlighting the need for further therapeutic validation.

• Canagliflozin Workflows for Renal Research

  2026-09-02

  Build renal and metabolic assays around Canagliflozin’s selective SGLT2 activity, then extend glucose measurements with mitochondrial structure, respiration, and albuminuria endpoints. This practical workflow emphasizes solvent control, sex-aware analysis, and model-specific interpretation for more informative diabetes and kidney studies.

• Diphenyleneiodonium chloride in Cell Assays

  2026-09-02

  Diphenyleneiodonium chloride (DPI), SKU B6326, can help researchers separate redox-enzyme effects from assay artifacts in viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers mechanism, solvent compatibility, protocol design, interpretation, and practical vendor selection.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-01

  The reference study identifies CD44 as a metabolic dependency created by IDH mutation in leukemia. Its results connect CD44-driven glucose rerouting to NADPH supply and R-2HG production, supporting combined targeting of mutant IDH and CD44 as a strategy for acute myeloid leukemia research.

• Fenipentol: From Chuanxiong Signal to Translation

  2026-09-01

  Fenipentol (1-Phenyl-1-pentanol) offers translational researchers a defined small-molecule entry point into secretory physiology, ESR1-linked signaling, and the source-resolved pharmacology of Ligusticum chuanxiong. This article connects mechanistic hypotheses with validation strategy, formulation discipline, toxicology context, and a differentiated path beyond conventional product-page descriptions.

• Angiotensin I/II (1-5) Protocol Guide

  2026-08-31

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research, including blood pressure and aldosterone-related assays. It is intended for validated cardiovascular or renal models and should not be treated as interchangeable with full-length angiotensin peptides or applied to unrelated signaling workflows without independent validation.

• 5-(N,N-dimethyl)-Amiloride in Endothelial Models

  2026-08-31

  Use 5-(N,N-dimethyl)-Amiloride hydrochloride as a pharmacological probe to connect Na+/H+ exchanger activity with intracellular pH regulation, endothelial barrier failure, and cardiac injury phenotypes. This workflow combines real-time ion measurements with permeability, signaling, and moesin assays while clearly separating established evidence from testable sepsis-model hypotheses.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-08-30

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also expose the activation-loop phospho-threonine to WIP1, accelerating dephosphorylation. Its structural and biochemical results introduce a conformation-focused strategy for improving kinase-inhibitor potency and specificity while clarifying how kinase state may influence phosphatase recognition.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-08-29

  The PKH26 Red Fluorescent Cell Linker Kit supports red fluorescent labeling of cell membrane lipid regions for cell tracing and proliferation-oriented assays. It is intended for membrane labeling in in vitro and in vivo workflows, not for intracellular targets or non-membrane labeling, and exact labeling conditions should be established from the kit instructions and cell-specific optimization.

8570 records 1/572 page Next 12345 下5页 Last page